2,6-diaminopurine has been researched along with Cystic Fibrosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amand, S; Arhant, G; Bailly, C; Beekman, J; Bourban, C; Chamaillard, M; Essonghe, NC; Gérardin, M; Gizzi, P; Guilbert, R; Hannebique, D; Hubert, D; Kong, R; Lejeune, F; Leroy, C; Persoons, P; Poix, V; Prevarskaya, N; Prévotat, A; Rebuffat, S; Reix, P; Shapovalov, G; Spelier, S | 1 |
1 other study(ies) available for 2,6-diaminopurine and Cystic Fibrosis
| Article | Year |
|---|---|
Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis.
Topics: Animals; Codon, Nonsense; Codon, Terminator; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Mice | 2023 |